Quoin Pharma gets EMA Orphan Drug Designation for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals, Ltd.

EMA grants Orphan Drug Designation for QRX003, a topical treatment for Netherton Syndrome, a rare disease with no approved therapies.
ODD provides 10 years of market exclusivity in Europe upon approval, plus fee reductions and access to EU grants.
QRX003 is in multiple late-stage clinical trials; CEO cites skin healing and pruritus elimination in pediatric study.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.